
Boehringer expands neurology activities
Since 2014, the partners have launched three preclinical research projects in COPD, neuroscience and innate immunity. The new project at BioMed X...

Diabetes doubles risk for heart failure
Recent clinical trials of new glucose-lowering treatments have drawn attention to the importance of hospitalization for heart failure as a...

GSK swallows Tesaro in US$5.1bn deal
In 2014 GlaxoSmithKline handed its oncology portfolio to Novartis in a US$16bn deal. Though the take-over appeared like a reentry the highly...

MEPs back €120bn budget for Horizon Europe
While the EU will miss its target to raise total public and private R&D spending in the EU to 3% of GDP by 2020 - in 2017 the EU average was...

EMA greenlights two orphan drugs and two biosimilars
Two of six new meds to be approved in Europe are biosimilar medicines and have been backed by the European Medicines Agency (EMA) this...

Staten Biotechnology in $430m deal with Novo Nordisk
Under the agreement, Dutch Staten Biotechnology B.V. and Novo Nordisk A/S will collaborate to co-develop Staten's preclinical dyslipidemia...

Medicxi put €40m into two Sosei spin off companies
The newly created companies Orexia Ltd and Inexia Ltd aim to develop orally or intranasally administered drug candidates to treat...